Documentation Centre

 

 

  of 101 Next page

Go to page: of

Screenshot Date Categories Title Author Format
Intensive blood pressure lowering in patients with and patients without type 2 diabetes: A pooled analysis from two randomized trials. Diabetes Care. 2018 Jun;41(6):1142-1148 September 20, 2018 Intensive blood pressure lowering in patients with and patients without type 2 diabetes: A pooled analysis from two randomized trials. Diabetes Care. 2018 Jun;41(6):1142-1148 Brouwer TF, Vehmeijer JT, Kalkman DN, Berger WR, van den Born BH, Peters RJ, Knops RE Key Publications
Peter Libby MD and CANTOS. Eur Heart J. 2018;39:1504-1505 August 29, 2018 Peter Libby MD and CANTOS. Eur Heart J. 2018;39:1504-1505 Ozkan J Key Publications
Impact of intensive lifestyle intervention on disability-free life expectancy: The Look AHEAD study. Diabetes Care. 2018;41:1040-1048 August 02, 2018 Impact of intensive lifestyle intervention on disability-free life expectancy: The Look AHEAD study. Diabetes Care. 2018;41:1040-1048 Gregg EW, Lin J, Bardenheier B, Chen H, Rejeski WJ, Zhuo X, Hergenroeder AL, Kritchevsky SB, Peters AL, Wagenknecht LE, Ip EH, Espeland MA; Look AHEAD Study Group. Key Publications
The effect of dietary glycemic index and glycemic load on inflammatory biomarkers: a systematic review and meta-analysis of randomized clinical trials. Am J Clin Nutr. 2018;107:593-606 July 24, 2018 The effect of dietary glycemic index and glycemic load on inflammatory biomarkers: a systematic review and meta-analysis of randomized clinical trials. Am J Clin Nutr. 2018;107:593-606 Milajerdi A, Saneei P, Larijani B, Esmaillzadeh A Key Publications
Effects of bariatric surgery in obese patients with hypertension: The GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137:1132-1142. June 21, 2018 Effects of bariatric surgery in obese patients with hypertension: The GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137:1132-1142. Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, Frayha JC, et al. Key Publications
The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study. J Hypertens. 2018;36:916-923 June 14, 2018 The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study. J Hypertens. 2018;36:916-923 Okin PM, Kjeldsen SE, Devereux RB Key Publications
Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: A Randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41:538-546 May 31, 2018 Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: A Randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41:538-546 Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S Key Publications
Changes in gut microbiota-related metabolites and long-term successful weight loss in response to weight-loss diets: The POUNDS lost trial. Diabetes Care. 2018;41:413-419 May 30, 2018 Changes in gut microbiota-related metabolites and long-term successful weight loss in response to weight-loss diets: The POUNDS lost trial. Diabetes Care. 2018;41:413-419 Heianza Y, Sun D, Smith SR, Bray GA, Sacks FM, Qi L Key Publications
Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study. Circ Genom Precis Med. 2018;11:e001696 May 30, 2018 Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study. Circ Genom Precis Med. 2018;11:e001696 Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen TR, Baigent C, Collins R, Landray M, Armitage J; HPS2-THRIVE Collaborative Group Key Publications
Therapeutic lowering of lipoprotein(a): A role for pharmacogenetics? Circ Genom Precis Med. 2018;11:e002052 May 30, 2018 Therapeutic lowering of lipoprotein(a): A role for pharmacogenetics? Circ Genom Precis Med. 2018;11:e002052 Boffa MB, Koschinsky M Key Publications

  of 101 Next page

Go to page: of